moneyheap
ADXN −10.02% today · Analysis updated Nov 13, 2026, 9:50 AM ET
Why is Addex Therapeutics (ADXN) stock down today?
ADXN jumped about 83% to $5.29 on Nov 12 from $2.89 the day before. Volume was about 22.3M shares, against typically a few thousand shares a day. The trigger was news that its former subsidiary Neurosterix closed a $105M Series B to fund Phase 2 development of the schizophrenia candidate NTX-253. Addex didn't take part in the round, and its stake is now 8.5%, valued at about $18.6M. That is a large value relative to Addex's tiny market cap. It gives investors a concrete, if indirect, asset. Today the stock is at $4.76, about 10% below yesterday's close, so some of the gain is already fading. The company's own financials are weak: revenue is negligible, losses are ongoing, and cash is thin. The stock also has a history of sharp spikes followed by fades, such as in August, when it ran above $10 and then sold off. Illiquidity and volatility are extreme, and the share price is still well above the $2.79 to $2.99 range of recent weeks.
News behind the analysis
- Addex Shares Surge As Neurosterix Closes $105M Financing To Advance Schizophrenia ProgramAddex's former subsidiary Neurosterix closed a $105M Series B to fund Phase 2 development of NTX-253. Addex didn't participate, and its stake was diluted to 8.5%, worth about $18.6M.
- Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%ADXN rose 71% on the Neurosterix financing news. The stock was trading at $4.61 at the time of the report.
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionADXN rose 74.0% to $5.03 in pre-market trading.
- 12 Health Care Stocks Moving In Thursday's Intraday SessionADXN was up 73.5% at $5.01 during the regular session.
- ADXN Stock Quote Price and ForecastADXN closed at $5.29, up 83.04% from the prior close. Quarterly revenue is tiny and net income is negative, and the company is a micro-cap.
- ADXN Stock Volatile As Traders Focus On Liquidity And Deep LossesIn August the stock spiked above $10 and then sold off hard. The report notes only about $3.3M in cash and very large losses relative to revenue.